ABBVIE (ABBV) DIvidends Date & History

Key Takeaways

• ABBV pays a quarterly dividend of $1.73 per share, or $6.92 on an annualized basis, with a dividend yield of roughly 2.9%.
• AbbVie has raised its dividend every year since its 2013 spin-off, extending a 53-year streak of consecutive annual increases inherited from Abbott Laboratories.
• The most recent increase was 5.5%, and the five-year average annual dividend growth rate is in the mid-to-high single digits.
• The dividend appears well covered by adjusted earnings and free cash flow, despite an elevated payout ratio on reported (GAAP) earnings.
• The stock is best suited to dividend growth and long-term income investors rather than investors seeking maximum current yield.

Dividend Overview

AbbVie Inc. (ABBV), the pharmaceutical company spun off from Abbott Laboratories in 2013, is widely regarded as a dividend growth stock rather than a pure high-yield play. The company currently pays a quarterly dividend of $1.73 per share, which translates to $6.92 per share annually and a dividend yield of approximately 2.9%—comfortably above the broader market average. Dividends are paid on a consistent quarterly schedule, typically with record and payment dates falling in the middle and second half of each quarter. While the yield is not the highest in the pharmaceutical sector, AbbVie's combination of a reliable payout, steady increases, and a large, diversified product portfolio positions it as a cornerstone holding for investors who prioritize both income and long-term dividend growth over chasing the highest immediate yield.

Dividend History and Growth

AbbVie has built one of the most consistent dividend track records in the healthcare sector. The company has increased its payout every year since becoming an independent public company in 2013, a discipline that extends a 53-year streak of consecutive annual dividend increases dating back to its time under Abbott Laboratories. In its most recent announcement, AbbVie raised the quarterly dividend by 5.5% to $1.73 per share. Over the past five years, the dividend has grown at an average annual rate of roughly 6% to 8%, reflecting steady, mid-single-digit increases rather than aggressive hikes. This measured approach has allowed AbbVie to grow the cumulative dividend by more than 330% since the spin-off while maintaining the financial flexibility to fund research and development and strategic acquisitions. The long-term strategy is clearly oriented toward dependable, compounding dividend growth.

Dividend Sustainability and Payout Ratio

Assessing AbbVie's dividend sustainability requires looking beyond headline earnings. On a reported (GAAP) basis, the payout ratio can appear elevated because AbbVie's earnings are depressed by large non-cash amortization and impairment charges tied to past acquisitions, including Humira and Allergan. On an adjusted (non-GAAP) earnings basis, which better reflects the company's underlying profitability, the payout ratio is generally in the range of roughly 50% to 70%. More importantly, AbbVie's dividend is comfortably supported by free cash flow (the cash a company generates after capital spending), with a free cash flow payout ratio of roughly 67%. AbbVie's diversified immunology and oncology franchises—led by Skyrizi and Rinvoq—have largely offset declining Humira sales, providing a stable earnings base. This combination of durable cash generation and a disciplined payout structure suggests the dividend is sustainable, with room for continued modest increases.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical peer group, AbbVie's yield of approximately 2.9% is above the median for the drug-manufacturing industry, which typically sits below 2.5%. It is higher than the yields offered by growth-oriented names such as LLY (Eli Lilly) and roughly in line with JNJ (Johnson & Johnson), MRK (Merck), and AMGN (Amgen). By contrast, PFE (Pfizer) and BMY (Bristol Myers Squibb) offer noticeably higher yields but have exhibited less consistent recent earnings and dividend momentum. AbbVie's positioning—a moderate yield paired with a dependable multi-decade growth streak—places it in a balanced middle ground: it rewards investors with a solid income stream while still prioritizing annual payout growth, a combination that distinguishes it from both high-yield value names and lower-yield growth names.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market efficiently. It scans thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. The screener can also be used to surface dividend stocks and income-focused investments, as well as trending names, breakout candidates, and other market opportunities, all driven by AI-based signals. By automating much of the research process, the AI Screener helps users identify potential opportunities more quickly than manual screening. Investors seeking dividend-paying stocks or stocks with strong dividend growth can use it to narrow the universe and compare candidates side by side.

Is This Stock Attractive for Dividend Investors?

AbbVie is likely to appeal most to dividend growth investors and long-term income investors who value reliability over maximizing current yield. With a yield near 2.9% and a 53-year record of consecutive annual increases, the stock offers a compelling blend of income and compounding growth potential, making it a natural fit for investors building a long-term, buy-and-hold portfolio. Conservative investors may also appreciate the company's diversified pharmaceutical portfolio and consistent free cash flow generation, which support the payout through industry cycles. On the other hand, investors seeking the highest possible current income or those who prefer more aggressive dividend growth may find AbbVie's yield and mid-single-digit increase rate comparatively modest. As with any equity, the value of the dividend must be weighed against stock price risk and the inherent uncertainties of the pharmaceutical industry, including patent expirations and regulatory developments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations